SCHEMBL31029670

SCHEMBL31029670

CC(C)(C)OC(=O)N1CCN(c2ncnc3ccc(Cl)nc23)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 2/20 0.62
CNR1 P21554 1/20 0.52
CNR2 P34972 1/20 0.52
KIT P10721 2/20 0.50
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
GBA1 P04062 2/20 0.47
POLB P06746 1/20 0.46
CKS1B P61024 2/20 0.45
SKP1 P63208 2/20 0.45
SKP2 Q13309 2/20 0.45
MAPT P10636 2/20 0.42
TSHR P16473 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
TLR9 Q9NR96 3/20 0.42
TLR7 Q9NYK1 2/20 0.42
PDE10A Q9Y233 1/20 0.42
ACHE P22303 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30902260 1.00 MAP4K4 (0.62) MAP4K4CNR1CNR2KITMEN1
SCHEMBL31029618 0.87 MAP4K4 (0.48) MAP4K4CNR1CNR2KITMEN1
SCHEMBL30902201 0.87 MAP4K4 (0.48) MAP4K4CNR1CNR2KITMEN1
SCHEMBL30902192 0.84 MAP4K4 (0.48) MAP4K4CNR1CNR2MEN1KMT2A
SCHEMBL31029643 0.84 MAP4K4 (0.48) MAP4K4CNR1CNR2MEN1KMT2A
SCHEMBL25389645 0.84 MAP4K4 (0.53) MAP4K4CNR1CNR2MEN1KMT2A
SCHEMBL31185561 0.84 MAP4K4 (0.53) MAP4K4CNR1CNR2MEN1KMT2A
SCHEMBL12276928 0.82 MEN1 (0.64) MAP4K4CNR1CNR2MEN1KMT2A
SCHEMBL3925621 0.82 MAP4K4 (0.43) MAP4K4CNR2MAPTSMN1; SMN2ALDH1A1
SCHEMBL30333588 0.82 MAP4K4 (0.43) MAP4K4CNR2MAPTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250145589-A1 PYRIDINE DERIVATIVE AND USE THEREOF SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) 2025-05-08 US disclosed
EP-4406948-A1 PYRIDINE DERIVATIVE AND USE THEREOF Sichuan Huiyu Pharmaceutical Co., Ltd. (CN) 2024-07-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145589-A1 PYRIDINE DERIVATIVE AND USE THEREOF KRAS, NRAS, BRAF MAP4K4 253/4885CNR1 2832/4885CNR2 3039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.